The FEBS Junior Section is organised by students and young researchers from some FEBS Constituent Societies. They develop joint activities, such as online talks and other events, and share resources, as well as open doors for young European scientists to opportunities outside their home countries by providing the relevant contacts and fostering communication within the network.

Ex-academia, now in MedComms. I write a blog called Total Internal Reflection about the human side of science. Postings are generally either opinion/commentary (either serious or silly) or "How To" pieces aimed at improving young scientists' soft skills.  A longer biography and manifesto are on the blog here.

biochemistry, molecular biology, bioinformatics, molecular visualisation, technology for teaching and learning

EMBL-EBI is international, innovative and interdisciplinary, and a champion of open data in the life sciences. We are part of the European Molecular Biology Laboratory (EMBL), an intergovernmental research organisation funded by over 20 member states, prospect and associate member states. We are situated on the Wellcome Genome Campus near Cambridge, UK, one of the world’s largest concentrations of scientific and technical expertise in genomics.

iam graduated from faculty of science, chemistry and biochemistry dep. i have a biomedical analysis diploma. my master degree focused in treatment diabetes with the combination therapy using natural products and a pharmaceutical. i hope to find a PHD position in biochemistry. mainly my interest in biochemistry. title of thesis( treatment of HFD induced diabetes with combination of metformin and natural products)

Dr. Abraham Lin is no stranger to interdisciplinary research, having a background in Nuclear Engineering (B.S.E) from the University of Michigan – Ann Arbor, Biomedical Engineering (PhD) from Drexel University, and now working as a joint postdoctoral researcher in the Center for Oncological Research (CORE) and the Plasma Lab for Sustainability and Medicine – Antwerp (PLASMANT) at the University of Antwerp, Belgium. Previously, he worked for NASA, where he studied using plasma, an ionized gas, for space propulsion before transitioning to study how the same technology can be used for cancer immunotherapy. Now, he is part of a team (Orbits) that is investigating how computer vision and artificial intelligence can be applied for advanced image analysis to unlock the full potential of next-generation, ‘patient-in-the-lab’ cancer models, known as patient-derived organoids. He hopes that by integrating these different technologies together, he can help researchers predict how cancer patients will respond to different therapies in the clinic. This could ultimately help researchers develop more effective drugs and help clinicians move towards more personalized cancer medicine.